Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Infliximab Biosimilar in Takayasu's Arteritis (TAKASIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03192878
Recruitment Status : Unknown
Verified June 2017 by Lorenzo Dagna, Ospedale San Raffaele.
Recruitment status was:  Recruiting
First Posted : June 20, 2017
Last Update Posted : June 20, 2017
Sponsor:
Information provided by (Responsible Party):
Lorenzo Dagna, Ospedale San Raffaele

Brief Summary:

Takayasu arteritis (TA) is a chronic inflammatory disease affecting large and medium caliber arteries, particularly the aortic arch and its main branches. Clinical manifestations are caused by the marked thickening of the wall of the involved vessels, resulting in lumen narrowing and ischemia of the tributary districts. Therapy is based on the use of corticosteroids, immunosuppressants, and biologic drugs including infliximab, a monoclonal antibody blocking tissue necrosis factor (TNF)-alpha. Biosimilar infliximab is commercially available and used in the treatment of various immune-mediated conditions. There are currently no data on the efficacy and safety of biosimilar infliximab in the treatment of TA.

The investigators propose this monocentric, observational, prospective, open label study to evaluate the efficacy and safety of biosimilar infliximab in the treatment of 30 patients with TA. Specifically, the study will include: I) TA patients refractory to treatment with corticosteroid and/or immmunosuppressive therapy, not previously treated with infliximab; II) TA patients already receiving treatment with originator infliximab.

Biosimilar infliximab will be administered at dosages usually employed in the treatment of TA. Specifically, patients not previously treated with the originator drug will receive biosimilar infliximab intravenously at a dose of 5 mg/Kg at time 0, at week 2, at week 4; thereafter, treatment will be administered every 4-6 weeks at a dose of 5-10 mg/kg based on clinical judgement. In patients previously treated with the originator drug, biosimilar infliximab will be administered at the same dosages.

To evaluate the efficacy of therapy, changes in clinical manifestations, laboratory examinations, and imaging findings including angio-magnetic resonance imaging (MRI) of thoracic and abdominal vessels and total body PET/CT scan will be evaluate at time 0 as well as 6 and 12 months following treatment initiation. In order to evaluate the safety of the study treatment, the investigators will stringently evaluate possible side effects of treatment, including infusion reactions, changes in laboratory tests, infection, cancer, autoimmune manifestations, neurological and cardiovascular symptoms.

The total duration of follow up for each patient will be 52 weeks from enrolment.


Condition or disease Intervention/treatment
Takayasu Arteritis Drug: Infliximab

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments
Actual Study Start Date : March 1, 2017
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab

Group/Cohort Intervention/treatment
Naive patients
Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
Drug: Infliximab
infliximab biosimilar

Switch patients
Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
Drug: Infliximab
infliximab biosimilar




Primary Outcome Measures :
  1. Number of patients with active disease at month 6 [ Time Frame: 6 months of treatment ]
    Disease will be defined active when new vascular lesion(s) (aneurysms, stenoses or occlusions, new arterial-wall irregularities) will be detected in arteries (aorta, innominate, subclavian, axillary, common and internal carotid, vertebral, superior and inferior mesenteric, renal, common iliac, and celiac axis) by MRI angiography or when increased arterial glucose uptake will be detected by FDG-PET scanning. Disease will also be defined active if at least 2 of the following will be present: 1) new onset of carotodynia or pain over large vessels, 2) transient ischemic episodes not attributable to other factors, 3) new bruit or new asymmetry in pulses or blood pressure determination, 4) ischemic symptoms (including new-onset claudication), and 5) fever in absence of infection

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 12 months of treatment ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at month 12


Secondary Outcome Measures :
  1. Number of patients with active disease at month 12 [ Time Frame: 12 months of treatment ]
    Disease will be defined active when new vascular lesion(s) (aneurysms, stenoses or occlusions, new arterial-wall irregularities) will be detected in arteries (aorta, innominate, subclavian, axillary, common and internal carotid, vertebral, superior and inferior mesenteric, renal, common iliac, and celiac axis) by MRI angiography or when increased arterial glucose uptake will be detected by FDG-PET scanning. Disease will also be defined active if at least 2 of the following will be present: 1) new onset of carotodynia or pain over large vessels, 2) transient ischemic episodes not attributable to other factors, 3) new bruit or new asymmetry in pulses or blood pressure determination, 4) ischemic symptoms (including new-onset claudication), and 5) fever in absence of infection

  2. Impact of the treatment on quality of life as assessed by the HAQ questionnaire [ Time Frame: 6 months of treatment ]
    We will evaluate the changes from baseline in the HAQ questionnaires at month 6

  3. Impact of the treatment on quality of life as assessed by the HAQ questionnaire [ Time Frame: 12 months of treatment ]
    We will evaluate the changes from baseline in the HAQ questionnaires at month 12

  4. Impact of the treatment on quality of life as assessed by the SF36 questionnaire [ Time Frame: 6 months of treatment ]
    We will evaluate the changes from baseline in the SF36 questionnaire at month 6

  5. Impact of the treatment on quality of life as assessed by the SF36 questionnaire [ Time Frame: 12 months of treatment ]
    We will evaluate the changes from baseline in the SF36 questionnaire at month 12

  6. Changes in the serum levels of TNF-alpha and anti-infliximab antibodies before and upon treatment with biosimilar infliximab. [ Time Frame: 6 months of treatment ]
    Levels of TNF-alpha and anti-infliximab antibodies will be determined by an immunoenzymatic assay and compared to reference ranges provided by the manufacturer. Serum levels of TNFα are expected to decrease upon treatment with biosimilar infliximab; generation of anti-infliximab antibodies may occur in some patients and may be associated with reduced treatment efficacy.

  7. Changes in the serum levels of TNF-alpha and anti-infliximab antibodies before and upon treatment with biosimilar infliximab. [ Time Frame: 12 months of treatment ]
    Levels of TNF-alpha and anti-infliximab antibodies will be determined by an immunoenzymatic assay and compared to reference ranges provided by the manufacturer. Serum levels of TNFα are expected to decrease upon treatment with biosimilar infliximab; generation of anti-infliximab antibodies may occur in some patients and may be associated with reduced treatment efficacy.


Biospecimen Retention:   Samples Without DNA
serum, plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

We anticipate to include about 30 patients with Takayasu's arteritis (TA). Specifically, the study will include:

I) TA patients refractory to treatment with corticosteroid and/or immmunosuppressive therapy, not previously treated with infliximab (the naive arm).

II) TA patients refractory to treatment with corticosteroid and/or immmunosuppressive therapy, already receiving treatment with originator infliximab (the switch arm).

Criteria

Inclusion Criteria:

  • age> 18 years;
  • negative pregnancy test;
  • use of a reliable contraceptive method by all potentially fertile patients during the study and for the six months following the end of therapy;
  • diagnosis of TA according to the Classification criteria of the American College of Rheumatology 1990;
  • Multifocal vascular aortic and arterial involvement as evaluated by imaging examinations (angiography / angio-MRI / vascular ecocolordoppler / PET);
  • failure to respond to corticosteroid therapy after 6-8 weeks of prednisone therapy at a dose of 1 mg / Kg per day, or impossibility to reduce the dose of prednisone to 0.5 mg / Kg within 3 months of initiation of therapy and to less than 0.2 mg / kg per day within 6 months of initiation of therapy (may also include patients who, despite receiving combination therapy with prednisone and cyclophosphamide, azathioprine, methotrexate, cyclosporin A, mycophenolate mofetil, leflunomide and rapamycin for at least 3 months, could not reduce the prednisone dose to 0.5 mg / Kg per day within 3 months of initiation of therapy, or to less than 0.2 mg / kg per day within 6 months of initiation of therapy);
  • ongoing anti-TNF-alpha treatment with originator infliximab (inclusion criterion for the switch arm).

Exclusion Criteria:

  • history of lymphoproliferative disease or solid neoplasm in the last 5 years, with the exception of successfully treated and completely resolved squamous cell skin carcinoma;
  • history of uncontrolled diabetes, unstable cardiac ischaemia, congestive heart failure (NYHA class III and IV), active intestinal inflammatory disease, active peptic ulcer, recent stroke (within 3 months) and any other pathological conditions that, according to the treating physician, could expose the subject to the risk of adverse events;
  • serological tests for hepatitis B or C indicating an active infection;
  • history of HIV infection;
  • chronic infection, or severe infections requiring hospitalization or intravenous antibiotic treatment within 30 days prior to inclusion in the study, or requiring treatment with oral antibiotics within 14 days prior to enrollment;
  • ongoing pregnancy or lactation;
  • history of drug or alcohol abuse;
  • Previous diagnosis or signs of demyelinating disease of the central nervous system;
  • history of active tuberculosis, histoplasmosis or listeriosis;
  • previous infection with M. tuberculosis (as documented by chest x-rays and / or positive quantiferon test), in which case patients will only be enrolled after initiating prophylactic therapy according to current guidelines.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03192878


Contacts
Layout table for location contacts
Contact: Elena M Baldissera, MD +39022643 ext 7254 baldissera.elena@hsr.it
Contact: Giulio Cavalli, MD +39022643 ext 4683 cavalli.giulio@hsr.it

Locations
Layout table for location information
Italy
IRCCS Ospedale San Raffaele Recruiting
Milano, MI, Italy, 20132
Contact: Elena M Baldissera, MD    +39022643 ext 7254    baldissera.elena@hsr.it   
Contact: Giulio Cavalli, MD    +39022643 ext 4683    cavalli.giulio@hsr.it   
Sponsors and Collaborators
Ospedale San Raffaele
Investigators
Layout table for investigator information
Principal Investigator: Lorenzo Dagna, MD IRCCS H San Raffaele

Layout table for additonal information
Responsible Party: Lorenzo Dagna, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Ospedale San Raffaele
ClinicalTrials.gov Identifier: NCT03192878     History of Changes
Other Study ID Numbers: TakaSim
First Posted: June 20, 2017    Key Record Dates
Last Update Posted: June 20, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Lorenzo Dagna, Ospedale San Raffaele:
infliximab
biosimilars
treatment

Additional relevant MeSH terms:
Layout table for MeSH terms
Arteritis
Takayasu Arteritis
Aortic Arch Syndromes
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
Skin Diseases, Vascular
Skin Diseases
Infliximab
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents